Top

Radiation Oncology

Published in:

Open Access 01-12-2018 | Research

A comparison of treatment outcome between fiducial-based and bone-based image guided radiotherapy in prostate cancer patients

Authors: Aleksandra Napieralska, Wojciech Majewski, Roland Kulik, Grzegorz Głowacki, Leszek Miszczyk

Published in: Radiation Oncology | Issue 1/2018

Abstract

Background and purpose

To compare the clinical outcome in prostate cancer patients treated with radiotherapy using two forms of image guidance: bone-based (BB) or fiducial-based (FB).

Material and methods

This retrospective study consisted of 180 patients treated with kV-kV image-guided radiotherapy (IGRT) between the years 2008 and 2011. A total of 89 patients were aligned to pelvic bone (Group BB) and 91 patients to the fiducial implanted into prostate for image guidance (Group FB). Patients were treated to a total dose of 76 Gy in 38 fractions. The Cox Regression Model was used to evaluate the influence of clinical and treatment-related parameters on overall survival, biochemical progression and progression-free survival. Acute and late toxicity were evaluated based on the RTOG/EORTC criteria. Sexual function was assessed with QLQ PR-25 (EORTC QLQ forms). An assessment of the differences in patient daily set-up from the time of simulation was performed.

Results

The incidence of acute G2/G3 genitourinary (GU) and gastrointestinal (GI) toxicity was similar between groups. In the BB group, 34 patients had G2 and 5 had G3 GU acute toxicity - compared to 40 patients with G2 and 2 with G3 in the FB group. G2 and G3 GI acute toxicity was observed respectively in 24 patients and in 1 patient in the BB group compared to 18 patients with G2 and 1 patient with G3 toxicity in the FB group. The five-year incidence of late ≥G2 GU toxicity was 12% in both groups (p = 0.98) and ≥ G2 GI toxicity 19% (BB) vs 15% (FB, p = 0.55), respectively. The five-year progression-free survival rate was 87% in BB and 81% in the FB Group (p = 0.15). The 5-year Overall Survival rate (OS) was 80% (BB) vs 91% % (FB, p = 0.20), but the difference was most pronounced in the intermediate-risk group: 5-year OS of 93% (FB) and 75% (BB), respectively (p = 0.06). No significant changes were observed in sexual or erectile functioning as compared to that specified at the beginning of radiotherapy and between the FB and BB Groups.

Conclusion

When comparing bone-based to fiducial-based techniques, no differences in clinical outcomes or late toxicity were seen in this population. However, intermediate risk prostate cancer patients are those who might benefit most from implementation of fiducial-based IGRT.

Gómez-Millán J, Lara MF, Correa Generoso R, Perez-Rozos A, Lupiáñez-Pérez Y, Medina Carmona JA. Advances in the treatment of prostate cancer with radiotherapy. Crit Rev Oncol Hematol. 2015;95:144–53. https://doi.org/10.1016/j.critrevonc.2015.02.008.CrossRefPubMed

Ten Haken RK, Forman JD, Heimburger DK, Gerhardsson A, McShan DL, Perez-Tamayo C, et al. Treatment planning issues related to prostate movement in response to differential filling of the rectum and bladder. Int J Radiat Oncol Biol Phys. 1991;20:1317–24.CrossRef

Nabavizadeh N, Elliott DA, Chen Y, Kusano AS, Mitin T, Thomas CR Jr, Holland JM. Image guided radiation therapy (IGRT) practice patterns and IGRT's impact on workflow and treatment planning: results from a National Survey of American Society for Radiation Oncology members. Int J Radiat Oncol Biol Phys. 2016;94:850–7. https://doi.org/10.1016/j.ijrobp.2015.09.035.CrossRefPubMed

De Los Santos J, Popple R, Agazaryan N, Bayouth JE, Bissonnette JP, Bucci MK, et al. Image guided radiation therapy (IGRT) technologies for radiation therapy localization and delivery. Int J Radiat Oncol Biol Phys. 2013;87:33–45. https://doi.org/10.1016/j.ijrobp.2013.02.021.CrossRefPubMed

Das S, Liu T, Jani AB, Rossi P, Shelton J, Shi Z, Khan MK. Comparison of image-guided radiotherapy technologies for prostate cancer. Am J Clin Oncol. 2014;37:616–23. https://doi.org/10.1097/COC.0b013e31827e4eb9.CrossRefPubMed

Fraass BA, Jolly S, Eisbruch A. Conformal Therapy and Intensity- Modulated Radiation Therapy: Treatment planning, treatment delivery, and clinical results. In: clinical radiation oncology, 3^rd ed. Gunderson LL, Tepper JE, Philadelphia 2012; 15: 287–316.

Tanyi JA, He T, Summers PA, Mburu RG, Kato CM, Rhodes SM, et al. Assessment of planning target volume margins for intensity-modulated radiotherapy of the prostate gland: role of daily inter- and intrafraction motion. Int J Radiat Oncol Biol Phys. 2010;78:1579–85. https://doi.org/10.1016/j.ijrobp.2010.02.001.CrossRefPubMed

Chung HT, Xia P, Chan LW, Park-Somers E, Roach M 3rd. Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT. Int J Radiat Oncol Biol Phys. 2009;73:53–60. https://doi.org/10.1016/j.ijrobp.2008.03.015.CrossRefPubMed

Rudat V, Nour A, Hammoud M, Alaradi A, Mohammed A. Image-guided intensity-modulated radiotherapy of prostate cancer: analysis of interfractional errors and acute toxicity. Strahlenther Onkol. 2016;192:109–17. https://doi.org/10.1007/s00066-015-0919-y.CrossRefPubMed

10.

Khor R, Williams S. Contemporary issues in radiotherapy for clinically localized prostate cancer. Hematol Oncol Clin North Am. 2013;27:1137–62. https://doi.org/10.1016/j.hoc.2013.08.006.CrossRefPubMed

11.

Kupelian PA, Langen KM, Willoughby TR, Zeidan OA, Meeks SL. Image-guided radiotherapy for localized prostate cancer: treating a moving target. Semin Radiat Oncol. 2008;18:58–66.CrossRef

12.

Miszczyk L, Leszczyński W, Szczepanik K, Majewski W. Comparison of two image guided radiation therapy (IGRT) methods used for prostate cancer patients - CBCT and 2D-2D kV. Przeglad Lekarski. 2008;65:7–8.

13.

Langen KM, Willoughby TR, Meeks SL, Santhanam A, Cunningham A, Levine L, Kupelian PA. Observations on real-time prostate gland motion using electromagnetic tracking. Int J Radiat Oncol Biol Phys. 2008;71:1084–90. https://doi.org/10.1016/j.ijrobp.2007.11.054.CrossRefPubMed

14.

Goyal S, Kataria T. Image guidance in radiation therapy: techniques and applications. Radiol Res Pract. 2014;2014:705604. https://doi.org/10.1155/2014/705604.CrossRefPubMedPubMedCentral

15.

Dang A, Kupelian PA, Cao M, Agazaryan N, Kishan AU. Image-guided radiotherapy for prostate cancer. Transl Androl Urol. 2018;7:308–20. https://doi.org/10.21037/tau.2017.12.37.CrossRefPubMedPubMedCentral

16.

Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84:125–9. https://doi.org/10.1016/j.ijrobp.2011.11.047.CrossRefPubMed

17.

Valeriani M, Bracci S, Osti MF, Falco T, Agolli L, De Sanctis V, Enrici RM. Intermediate-risk prostate cancer patients treated with androgen deprivation therapy and a hypofractionated radiation regimen with or without image guided radiotherapy. Radiat Oncol. 2013;8:137. https://doi.org/10.1186/1748-717X-8-137.CrossRefPubMedPubMedCentral

18.

Sveistrup J, af Rosenschöld PM, Deasy JO, Oh JH, Pommer T, Petersen PM, Engelholm SA. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol. 2014;9:44. https://doi.org/10.1186/1748-717X-9-44.CrossRefPubMedPubMedCentral

19.

Singh J, Greer PB, White MA, Parker J, Patterson J, Tang CI, et al. Treatment-related morbidity in prostate cancer: a comparison of 3-dimensional conformal radiation therapy with and without image guidance using implanted fiducial markers. Int J Radiat Oncol Biol Phys. 2013;85:1018–23. https://doi.org/10.1016/j.ijrobp.2012.07.2376.CrossRefPubMed

20.

Gill S, Thomas J, Fox C, Kron T, Rolfo A, Leahy M, et al. Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiat Oncol. 2011;6:145. https://doi.org/10.1186/1748-717X-6-145.CrossRefPubMedPubMedCentral

21.

Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6. https://doi.org/10.1016/0360-3016(95)00060-C.CrossRefPubMed

22.

van Andel G, Bottomley A, Fosså SD, Efficace F, Coens C, Guerif S, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44:2418–24. https://doi.org/10.1016/j.ejca.2008.07.030.CrossRefPubMed

23.

Fiorino C, Valdagni R, Rancati T, Sanguineti G. Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol. 2009;93:153–67. https://doi.org/10.1016/j.radonc.2009.08.004.CrossRefPubMed

24.

Cozzarini C, Rancati T, Badenchini F, Palorini F, Avuzzi B, Degli Esposti C, et al. Baseline status and dose to the penile bulb predict impotence 1 year after radiotherapy for prostate cancer. Strahlenther Oncol. 2016;192:297–304. https://doi.org/10.1007/s00066-016-0964-1.CrossRef

25.

Nguyen DT, O'Brien R, Kim JH, Huang CY, Wilton L, Greer P, et al. The first clinical implementation of a real-time six degree of freedom target tracking system during radiation therapy based on Kilovoltage Intrafraction monitoring (KIM). Radiother Oncol. 2017;123:37–42. https://doi.org/10.1016/j.radonc.2017.02.013.CrossRefPubMed

Title: A comparison of treatment outcome between fiducial-based and bone-based image guided radiotherapy in prostate cancer patients
Authors: Aleksandra Napieralska
Wojciech Majewski
Roland Kulik
Grzegorz Głowacki
Leszek Miszczyk
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2018
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/s13014-018-1171-2

At a glance: The STEP trials

Springer Medicine

A comparison of treatment outcome between fiducial-based and bone-based image guided radiotherapy in prostate cancer patients

Abstract

Background and purpose

Material and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background and purpose

Material and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer

Comparison of efficacy and safety of preoperative Chemoradiotherapy in locally advanced upper and middle/lower rectal cancer

Evaluation of multiple institutions’ models for knowledge-based planning of volumetric modulated arc therapy (VMAT) for prostate cancer

Optimizing the prescription isodose level in stereotactic volumetric-modulated arc radiotherapy of lung lesions as a potential for dose de-escalation

Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy

The effects of prophylactic cranial irradiation versus control on survival of patients with extensive-stage small-cell lung cancer: a meta-analysis of 14 trials